Rosetta Genomics (ROSG) +4.7% premarket after announcing the commercial launch of the miRview...

|About: Rosetta Genomics Ltd. (ROSG)|By:, SA News Editor

Rosetta Genomics (ROSG) +4.7% premarket after announcing the commercial launch of the miRview mets assay, its flagship product, in the U.S. oncology market. miRview mets2 is a diagnostic tool for clinicians in the evaluation of cancer patients.